<DOC>
	<DOCNO>NCT00852228</DOCNO>
	<brief_summary>The primary objective study increase 15 % complete macroscopic resection rate predominantly liver metastasis metastatic colorectal cancer combine systemic cetuximab hepatic artery infusion three-drug chemotherapy ( irinotecan , oxaliplatin 5-fluorouracil ) .</brief_summary>
	<brief_title>Optimal Control Liver Metastases From Colorectal Cancer With Cetuximab Hepatic Artery Infusion Chemotherapy</brief_title>
	<detailed_description>Primary end-point : incidence complete macroscopic resection liver metastasis ( R0+R1 ) . Secondary end-points : - rate histologic complete response , - individual rate R0 R1 resection , - rate site ( ) relapse resect patient throughout 3-year span follow hepatectomy , , - relapse-free survival curve median resect patient , - progression-free overall survival patient receive least 4 full course HAI therapy patient ( intent treat ) , - objective response rate , - rate adverse event , - dose intensity 3 , 6 9 course , - per-operative post-operative complication associate liver surgery . The study also include pharmacokinetic analysis , translational research rest/activity monitoring investigation . Open , label , European , non randomize , multicenter , phase II study intravenous cetuximab ( ERBITUX® ) hepatic artery infusion three-drug chemotherapy ( irinotecan , 5-fluorouracil oxaliplatin ) use conventional chronomodulated delivery ( accord institution experience ) patient liver metastasis colorectal cancer . Patients undergo partial hepatectomy 6 ± 3 course therapy whenever possible . The minimum 3 maximum 9 course liver surgery depend upon result iterative onco-surgical evaluation . A minimum 6 9 additional course therapy administer surgery , depend upon result liver surgery , pathology report patient 's status . Overall , patient receive 9 18 course protocol therapy . The interval last course cetuximab-HAI chemotherapy surgery 2 4 week . Post operative treatment initiate 2 4 week liver surgery . TRANSLATIONAL RESEARCH : 1 . Pharmacokinetics : For subset 16 patient ( 8 conventional administration 8 chronotherapeutic delivery ) , plasma pharmacokinetics irinotecan , 5-FU oxaliplatin main metabolite evaluate first course . 2 . Rest-Activity monitoring : Rest-activity monitor wrist-worn actigraph ( Ambulatory Monitoring , USA ) 1 week prior treatment onset 2 week follow treatment onset ( 3 week ) . This evaluation repeat , 4th treatment course 7th treatment course . Participation center investigation leave optional . Time series analyze , chemotherapy course , time course follow parameter : - Autocorrelation coefficient 24 h ( r24 ) - Dichotomy index I &lt; O - Wavelet-based model function baseline , deviation model function treatment course delivery . 3 . Predictive molecular factor : In primary tumor and/or metastasis obtain time prior inclusion resect metastasis non tumoral liver : - EGFR immunohistochemistry gene expression amplification polymorphism . - K-ras mutation . - Clock gene polymorphism mRNA protein expression . - Gene polymorphisms expression main pharmacology determinant irinotecan , 5- FU oxaliplatin efficacy . - Inflammatory immune cell subset infiltration . Whenever possible , biopsy liver metastasis also obtain treatment onset document translational endpoint . In serum , upon inclusion 3 course : · Determination serum level TGFa , EGF , VEGF , IL-6 , IL-8 , amphiregulin epiregulin . In blood cell upon inclusion : · Constitutive polymorphism ADCC ( FCII FCIII ) , circadian clock EGFR . STATISTICAL METHODS AND SAMPLE SIZE : The main endpoint incidence macroscopically complete resection liver metastasis ( R0+R1 ) . The confidence interval ( CI ) response rate base exact binomial distribution . For secondary endpoint , rate histologic complete response , rate R0 resection , rate R1 resection , rate relapse , rate objective response , result estimate CI base exact binomial distribution . Overall survival time ( OS ) progression free survival ( PFS ) analyze Kaplan Meier curve . Multivariate analysis perform use Cox proportional hazard model . This analysis include follow factor : center , performance status , gender , liver disease characteristic , leucocyte count alkaline phosphatases upon inclusion treatment delivery schedule , Relapse incidence ( RI ) define probability relapse time t. Death without experience relapse compete event . The method analysis therefore estimation Cumulative Incidence curve compete risk set . Multivariate analysis perform Fine &amp; Gray model . All patient achieve complete remission analyze . The goal increase rate complete resection ( R0+R1 ) 15 % , i.e . 15 % ( p0=0.15 ) 30 % ( p1=0.30 ) . According exact single-stage phase II design method , trial accept p1 prefer p0 ( a=5 % b=20 % ) require 48 patient assessable response . To obtain 48 patient assessable response , 60 patient include trial . A major additional effect expect combined treatment modality increase complete histologic response , secondary endpoint trial , 5 % ( systemic chemotherapy ) 20 % combine cetuximab 3-drug HAI . This improvement reduce risk relapse liver outside liver 15 % , i.e . 80 % 65 % . Therefore , total number patient 60 patient , include 48 assessable 12 estimate unassessable technical reason ( i.e . HAI catheter dysfunction within first 2 month ) .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Histologically cytologically confirm carcinoma colon and/or rectum evidence liver metastasis ( new confirmation metastatic disease require case time interval last histological diagnosis enrolment exceed 3 year ) . Patient wild type ( WT ) KRAS tumor status Patient whose liver metastases consider non resectable curative intent medicosurgical staff meeting . In particular patient least one follow criterion , prevent complete local treatment liver metastasis surgery alone surgery plus radiofrequency ablation : le 30 % estimate residual liver resection disease contact liver main vessel document progressive disease image document double serum level carcinoembryonic antigen ( CEA ) CA19.9 past 90 day less Patient three resectable extrahepatic nodule &lt; = 10 mm One , two three prior chemotherapy line colorectal cancer . Written informed consent . Age &gt; =18 year . Patient must able comply protocol . Life expectancy least 3 month . At least one measurable metastatic liver lesion ( per RECIST criterion ) . World Health Organization performance status 0 1 . Adequate hematological function : absolute neutrophil count ( ANC ) &gt; =1.0 x 10^9/L ; platelet &gt; =75 x 10^9/L , hemoglobin ( Hb ) &gt; =8.5 g/dL . International normalized ratio ( INR ) &lt; =1.5 activate partial thromboplastin time ( aPTT ) &lt; =1.5 x upper limit normal ( ULN ) within 7 day prior start study treatment , absence anticoagulant therapy . Liver function : serum bilirubin &lt; =1.5 x ULN ; alkaline phosphatase transaminases &lt; 5 x ULN ( liver metastasis ) . Serum creatinine &lt; = 1.5 x ULN . Fertile woman men childbearing potential ( &lt; 2 year last menstruation woman ) must use effective mean contraception ( oral contraceptive , intrauterine contraceptive device , barrier method contraception conjunction spermicidal jelly surgically sterile ) . Patient whose primary tumor metastasis display mutation KRas ( codon 12 and/or 13 ) . Unresectable extrahepatic disease . More three resectable extrahepatic nodule . Size extra hepatic nodule &gt; 1 cm Prior HAI 3 drug . More 2 prior surgical attempt metastatic disease Prior radiotherapy metastatic disease Known document intolerance hypersensitivity drug use . Sensory neuropathy grade 3 ( National Cancer InstituteCommon Terminology Criteria Adverse Events NCICTCAE , Version 3.0 ) . Past current history ( within last 2 year prior treatment start ) malignancy colorectal cancer ( patient curatively treat basal squamous cell carcinoma skin situ carcinoma cervix eligible ) . Serious , non healing wound , ulcer , bone fracture . Evidence disease , metabolic dysfunction , physical examination find laboratory find give reasonable suspicion disease condition put patient high risk treatmentrelated complication . Pregnancy lactation Fertile woman ( &lt; 2 year last menstruation ) men childbearing potential willing use effective mean contraception . Prior systemic administration cetuximab antiEGFR agent exclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>colorectal cancer</keyword>
	<keyword>unresectable metastasis</keyword>
	<keyword>neo-adjuvant chemotherapy</keyword>
	<keyword>liver metastasis</keyword>
	<keyword>chronotherapy</keyword>
	<keyword>cetuximab</keyword>
	<keyword>irinotecan</keyword>
	<keyword>oxaliplatin</keyword>
	<keyword>5-fluorouracil</keyword>
	<keyword>hepatic artery infusion</keyword>
	<keyword>Unresectable hepatic lesion</keyword>
	<keyword>1 3 prior chemotherapy regimen</keyword>
</DOC>